Investigational senolytic drug combination · Fact sheet

Dasatinib plus quercetin

Also known as D+Q · DQ senolytic combination

Dasatinib plus quercetin is not FDA approved for aging, frailty, fibrosis, kidney disease, or cognitive decline. Early pilot studies show feasibility and biomarker effects—not proven clinical benefit—and dasatinib has serious labeled toxicities.

In clinical trialsEarly human evidence

What is Dasatinib plus quercetin?

Dasatinib is an FDA-approved kinase inhibitor for specific leukemias; quercetin is a plant flavonoid sold in supplements.

Researchers combine them because different senescent cell types may rely on different survival pathways. The experimental combination is a new claim set, not an extension of dasatinib's cancer approval.

Benefits & claims

Small studies in diabetic kidney disease and idiopathic pulmonary fibrosis reported changes in senescence markers or feasibility outcomes.

The approach directly tests a central geroscience hypothesis, but the human studies are far too small to establish improved disease or longevity outcomes.

What the evidence supports

  • A small diabetic-kidney-disease study reported lower senescent-cell markers after treatment.
  • Pulmonary-fibrosis pilots established feasibility but were not designed to prove disease modification.
Research areas
  • Cellular senescence
  • Idiopathic pulmonary fibrosis
  • Diabetic kidney disease
  • Frailty and aging biomarkers

Dosage & frequency

No established human regimen

Dasatinib is a prescription cancer drug; pairing it with quercetin for senolysis is experimental. An oncology dose is not an approved anti-aging schedule.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • The combination is distinct from quercetin supplementation alone.

Interactions & precautions

  • Dasatinib has important drug interactions and risks including cytopenias, bleeding and fluid retention; the oncology label cannot be reduced to a wellness protocol.

What is still unresolved

  • Which population, intermittent schedule, and long-term risk balance could support senolytic treatment?

Side effects & risks

  • Dasatinib labeling describes myelosuppression, bleeding, fluid retention, cardiovascular effects, pulmonary arterial hypertension, severe skin reactions, and major interaction risks.
  • Quercetin can add interaction and product-quality uncertainty.
  • Intermittent research exposure does not erase the serious pharmacology of an oncology medicine.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Human evidence consists of small pilot studies focused on feasibility, safety, physical measures, and senescence biomarkers. There is no adequate trial showing fewer diseases, sustained functional benefit, or longer life.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Better perceived exercise capacity, poorer sleep

A healthy man in his late 50s described improved cycling power, balance, grip strength, energy and mental clarity over seven weeks, but worse wearable sleep scores.

Reported use in this account

Product
Dasatinib plus quercetin
Amount
Dasatinib 200 mg plus quercetin 2,000 mg
Frequency
One reported administration
Route
Not specified clearly
Duration
Single administration; outcomes described 49 days later

Other exposures described: Rapamycin and metformin, used for 29 months according to the author

He was also using rapamycin and metformin. Measurements were self-reported, with no blinded control or verified evidence of senescent-cell removal.

Read the original account
Mixed account · personal report

Brief stimulation followed by heavy tiredness

A different commenter reported little initially, then a mild activated feeling and marked tiredness that night with unusually long sleep.

Amount, frequency, route and duration could not be confirmed for this account.

The account covered only two days of follow-up and did not include the promised exercise update. Its amount numbers lack units, so no amount is resolved; lasting benefit and safety cannot be established.

Read the original account

Approval status

The D+Q combination has no FDA-approved senolytic or geroscience use. Dasatinib alone is FDA approved for specific leukemia indications under prescription labeling.

Small clinical pilots, no approved senolytic use

Dasatinib alone is FDA approved for leukemia indications, but the dasatinib-plus-quercetin senolytic claim remains in small pilot research rather than a defined FDA approval path.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether senescence-marker changes improve any patient-centered outcome
  • Which senescent cell types are affected in each human tissue
  • Whether benefits could outweigh cancer-drug risks in people without cancer
  • Long-term and repeated-course safety

Summary

D+Q has early human research but no established anti-aging benefit. Dasatinib’s labeled risks also apply to the experimental combination.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Sprycel

    Dasatinib's approved cancer uses, warnings, adverse reactions, and interactions.

  2. pubmedD+Q diabetic kidney disease pilot

    Very small open-label human study of senescence markers rather than clinical efficacy.

  3. pubmedRandomized D+Q pulmonary-fibrosis pilot

    Small feasibility and tolerability study not powered for disease benefit.

  4. pubmedFirst-in-human D+Q pulmonary-fibrosis pilot

    Open-label pilot with no placebo comparison and major interpretive limits.

How we assess sources · Suggest a correction